Myriad Genetics | MYGN - Ebitda


Myriad Genetics reported $14.3M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Agilent USD 577M 77M Jun/2026
Becton, Dickinson and Co. USD 1.71B 1B Jun/2026
Bio-Rad Laboratories USD 119.9M 475.4M Sep/2026
Bruker USD 143.2M 33.2M Jun/2026
Danaher USD 2.1B 257M Sep/2026
Illumina USD 330M 80M Jun/2026
J&J USD 8.99B 721M Jun/2026
Mettler Toledo International USD 366.1M 43.45M Sep/2026
Myriad Genetics USD 14.3M 4M Dec/2025
OraSure Technologies USD -17.7M 4.06M Dec/2025
Pacific Biosciences Of California USD -35.4M 5.78M Sep/2025
Quest Diagnostics USD 627M 21M Sep/2026
Quidel USD 148M 18.7M Sep/2026
Repligen USD 43.84M 70K Sep/2026
Revvity USD 227.55M 629K Sep/2026
Standard Biotools USD -6.56M 1.45M Jun/2026
Thermo Fisher Scientific USD 3.79B 244M Sep/2026
Veracyte USD 41.24M 2.72M Sep/2026
Waters USD 554M 158M Sep/2026